Acumen's Phase 2 ALTITUDE-AD fails primary endpoint; sabirnetug development halted, cash conservation planned

Acumen Pharmaceuticals, Inc.

• Phase 2 ALTITUDE-AD missed the primary iADRS endpoint at 18 months vs placebo at both the 35 mg/kg and 50 mg/kg doses; CDR-SB and other key secondary endpoints were not significant.
• Sabirnetug was generally well tolerated; ARIA-E occurred in ~10% of treated participants; PET SUVr showed statistically significant amyloid plaque reduction at weeks 36 and 76.
• Acumen plans to cease development of sabirnetug, including the open-label extension portion of ALTITUDE-AD, and to implement cash conservation measures.
• Company will evaluate strategic options, including its Enhanced Brain Delivery (EBD) program, to maximize shareholder value.
• Additional fluid biomarker and imaging data expected in coming weeks, though Acumen does not expect it to change the trial's efficacy conclusions; CEO Daniel O'Connell commented.